Cellular reprogramming: a new approach to modelling Parkinson's disease.

Cellular reprogramming: a new approach to modelling Parkinson's disease.

iPSCs (induced pluripotent stem cells) offer an unparalleled opportunity to generate and study physiologically relevant cell types in culture. iPSCs can be generated by reprogramming almost any somatic cell type using pluripotency factors such as Oct4, SOX2, Nanog and Klf4. By reprogramming cells fr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hartfield, E, Fernandes, H, Vowles, J, Cowley, S, Wade-Martins, R
Formato:	Journal article
Lenguaje:	English
Publicado:	2012

Ejemplares similares

Physiological characterisation of human iPS-derived dopaminergic neurons
por: Hartfield, E, et al.
Publicado: (2014)

Physiological characterisation of human iPS-derived dopaminergic neurons
por: Hartfield, E, et al.
Publicado: (2014)

Parkinson's disease in a dish - Using stem cells as a molecular tool.
por: Badger, J, et al.
Publicado: (2014)

Parkinson's disease in a dish - Using stem cells as a molecular tool
por: Badger, J, et al.
Publicado: (2014)

Cellular α-synuclein pathology is associated with bioenergetic dysfunction in Parkinson's iPSC-derived dopamine neurons
por: Zambon, F, et al.
Publicado: (2019)

Protein-protein interaction networks identify targets which rescue the MPP+ cellular model of Parkinson's disease
por: Keane, H, et al.
Publicado: (2015)

Variant U1 snRNAs are implicated in human pluripotent stem cell maintenance and neuromuscular disease.
por: Vazquez-Arango, P, et al.
Publicado: (2016)

Physiological characterisation of human iPS-derived dopaminergic neurons.
por: Elizabeth M Hartfield, et al.
Publicado: (2014-01-01)

Transcriptomic profiling of purified patient-derived dopamine neurons identifies convergent perturbations and therapeutics for Parkinson's disease.
por: Sandor, C, et al.
Publicado: (2017)

Cell reprogramming therapy for Parkinson’s disease
por: Wenjing Dong, et al.
Publicado: (2024-01-01)

ER stress and autophagic perturbations lead to elevated extracellular α-Synuclein in GBA-N370S Parkinson's iPSC-derived dopamine neurons
por: Fernandes, H, et al.
Publicado: (2016)

Cellular reprogramming for understanding and treating human disease.
por: Riya Rajan Kanherkar, et al.
Publicado: (2014-11-01)

Neuroprotective Effects of Cryptotanshinone in a Direct Reprogramming Model of Parkinson’s Disease
por: Joo-Eun Lee, et al.
Publicado: (2020-08-01)

Epigenetic Dynamics in Reprogramming to Dopaminergic Neurons for Parkinson's Disease
por: Byounggook Cho, et al.
Publicado: (2024-11-01)

Astrocyte-to-neuron reprogramming and crosstalk in the treatment of Parkinson's disease
por: Yiming Wang, et al.
Publicado: (2023-08-01)

Commentary: Parkinson disease-linked GBA mutation effects reversed by molecular chaperones in human cell and fly models
por: Fernandes, H, et al.
Publicado: (2017)

Are rodent models of Parkinson's disease behaving as they should?
por: Vingill, S, et al.
Publicado: (2017)

Cellular Reprogramming and Its Potential Application in Alzheimer’s Disease
por: Chao Zhou, et al.
Publicado: (2022-04-01)

Network pharmacology of the MPP+ cellular model of Parkinson’s disease
por: Keane, H
Publicado: (2015)

RNA sequencing reveals MMP2 and TGFB1 downregulation in LRRK2 G2019S Parkinson's iPSC-derived astrocytes
por: Booth, H, et al.
Publicado: (2019)

Programming and reprogramming cellular identity
por: Marson, Alexander
Publicado: (2008)

Re: Epigenetics of Cellular Reprogramming
por: Fehmi Narter
Publicado: (2016-12-01)

Deterministic versus stochastic model of reprogramming: new evidence from cellular barcoding technique
por: Anastasia M. Yunusova, et al.
Publicado: (2017-01-01)

Convergent pathways in Parkinson’s disease
por: Cherubini, M, et al.
Publicado: (2017)

Advances in Cellular Reprogramming-Based Approaches for Heart Regenerative Repair
por: Xingyu He, et al.
Publicado: (2022-12-01)

Potential cellular and regenerative approaches for the treatment of Parkinson&rsquo;s disease
por: Emma L Lane, et al.
Publicado: (2008-08-01)

Cellular Reprogramming toward the Erythroid Lineage
por: Laura J. Norton, et al.
Publicado: (2011-01-01)

Single-cell sequencing of iPSC-dopamine neurons reconstructs disease progression and identifies HDAC4 as a regulator of Parkinson cell phenotypes
por: Lang, C, et al.
Publicado: (2018)

Epigenetic reprogramming shapes the cellular landscape of schwannoma
por: S. John Liu, et al.
Publicado: (2024-01-01)

Epigenetic determinants of cellular differentiation, transcriptional reprogramming, and human disease
por: Nguyen, Khoi Thien.
Publicado: (2021)

The Importance of Ubiquitination and Deubiquitination in Cellular Reprogramming
por: Bharathi Suresh, et al.
Publicado: (2016-01-01)

Dynamical systems theory of cellular reprogramming
por: Yuuki Matsushita, et al.
Publicado: (2022-04-01)

Cellular programming and reprogramming - Methods and protocols
por: CarloAlberto Redi
Publicado: (2010-12-01)

Implications of Cellular Aging in Cardiac Reprogramming
por: Fabiana Passaro, et al.
Publicado: (2018-04-01)

Neuroregeneration using in vivo cellular reprogramming
por: Tu Nguyen, et al.
Publicado: (2017-01-01)

The role of astrocyte dysfunction in Parkinson's disease pathogenesis
por: Booth, H, et al.
Publicado: (2017)

Induced pluripotent stem cell (iPSC)-derived dopaminergic models of Parkinson's disease.
por: Beevers, J, et al.
Publicado: (2013)

Parkinson’s Disease in a Dish: What Patient Specific-Reprogrammed Somatic Cells Can Tell Us about Parkinson’s Disease, If Anything?
por: J. Drouin-Ouellet, et al.
Publicado: (2012-01-01)

Exploring the Mitochondrial Degradome by the TAILS Proteomics Approach in a Cellular Model of Parkinson’s Disease
por: Marta Lualdi, et al.
Publicado: (2019-07-01)

New roles of glycosaminoglycans in α-synuclein aggregation in a cellular model of Parkinson disease.
por: Sonia Lehri-Boufala, et al.
Publicado: (2015-01-01)